ENTX Stock Summary and Trading Ideas (Entera Bio Ltd. - | NASDAQ:ENTX)

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.

As of February 6, 2026, ENTX stock price declined to $1.04 with 355,033 million shares trading.

ENTX has a beta of 0.38, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.01 to the broad based SPY ETF.

ENTX has a market cap of $47.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ENTX traded as high as $3.35 and as low as $.52.

ENTX has underperformed the market in the last year with a price return of -58.7% while the SPY ETF gained +15.1%. ENTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -66.6% and -35.0%, respectively, while the SPY returned +3.3% and +0.2%, respectively.

ENTX support price is $1.09 and resistance is $1.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX shares will trade within this expected range on the day.